


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Eric S. Lander, Michele Cargill, James S. Ireland, Stacey Bolk, George Q. Daley
and Jeanette J. McCarthy
Application No.: 09/657,472 Group Art Unit: 1634
Filed: September 7, 2000 Examiner: J.E. Souaya
Confirmation No.: 1705
Title: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☐ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☒ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☒ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

01/07/2003 09:57:47Z 09657472

01/07/2003 09:57:47Z 09657472

180.00 CH

01 FC:1806

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references (AU-AX) are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

[X] Applicants request that the following non-published pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. 60/300,158, by George Q. Daley, Stacey Bolk and Jeanette J. McCarthy, filed June 22, 2001, Docket No.: 2825.2029-000

U.S. Patent Application No. 10/007,781, by Stacey Bolk, George Q. Daley and Jeanette J. McCarthy, filed November 13, 2001, Docket No.: 2825.2025-001

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

[X] A copy of each above-cited application, including the current claims, is enclosed.

[] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[X] Please charge Deposit Account 08-0380 in the amount of \$ 180. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Pamela A. Torpey
Pamela A. Torpey
Registration No.: 45,736
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: December 30, 2002

APPLICATION NO.
09/657,475

APPLICANT
Eric S. Lander, et al.

December 30, 2002

FILING DATE
September 7, 2000

CONFIRMATION NO.
1705

GROUP
1634

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

OTHER DOCUMENTS (Including Author, Title, Date, Volume)	
AU	Schymkowitz, J.W.H., et al., "Sequence Conservation Provides the Best Prediction of the Role of Proline Residues in p13suc1," <i>J. Mol. Biol.</i> , 301:199-204 (2000).
AV	Kyriakides, T.R., "Mice That Lack Thrombospondin 2 Display Connective Tissue Abnormalities That Are Associated with Disordered Collagen Fibrillogenesis, an Increased Vascular Density, and a Bleeding Diathesis," <i>J. Cell Biol.</i> , 140(2):419-430 (1998).
AW	Yang, Z., et al., "Matricellular Proteins as Modulators of Cell-Matrix Interactions: Adhesive Defect in Thrombospondin 2-null Fibroblasts in a Consequence of Increased Levels of Matrix Metalloproteinase-2," <i>Mol. Biol. Cell</i> , 11(10):3353-3364 (2000).
AX	Lawler, J., et al., "Characterization of Human Thrombospondin-4*," <i>J. Biol. Chem.</i> , 270(6): 2809-2814 (1995).

DATE CONSIDERED